Full history for every metric is available with a Kvantra account

Stock profile
10x Genomics, Inc. logo

10x Genomics, Inc. (TXG)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
N/A
History
P/E NTM
N/A
Market cap
6.29B
Currency USD
KvantraRankAbout78
IValue62
IIQuality81
IIIMomentum99
Current price
51.80 USD-9.72%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m299490516619611643619630
Operating profit$m-111-72
Net profit$m-543-58-166-255-183-44-67-77
EPS reported$-0.35-0.52
Operating cashflow per share$1.090.76
Capex per share$0.050.05
FCF per share$1.040.72
Free cash flow$m13094
Net debt$m-366-500
Book value equity$m796838
Book value per share$6.386.41
Number of sharesm124.75130.81
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx--
P/B LTMx2.567.51
P/S LTMx3.1710.17
P/FCF LTMx15.6467.09
EV/EBITDA LTMx439.61129.72
EV/Sales LTMx2.679.36
Earnings Yield LTM%-2.14%-0.99%
FCF Yield%6.39%1.49%
Quality
ROE%-5.47%-8.19%
ROIC%-12.34%-7.72%
Operating margin%-17.25%-11.67%
Gross margin%69.05%71.88%
FCF/Sales%20.24%15.16%
Growth and momentum
EPS Growth YoY%--
Sales Growth YoY%+5.25%-3.62%
Net Income Growth YoY%--
FCF Growth%-+14.84%
Operating Profit Growth%--
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%--
FCF/Debtx0.821.24
Net Debt/EBITDAx-80.90-10.09
EBIT/Net interestx--
Net debt/market cap%-17.97%-7.95%
Net debt/Equityx-0.46-0.60
Gross debt/equityx0.200.09

ETFs that hold 10x Genomics

FundTickerPosition#Weight
Vanguard Russell 2000 ETFVTWO40.35%
Principal U.S. Small-Cap Multi-Factor ETFPSC40.84%
ARK Genomic Revolution ETFARKG27.87%
Vanguard Russell 2000 Growth ETFVTWG40.69%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC30.46%
Invesco Dorsey Wright Healthcare Momentum ETFPTH102.97%
Amplify Etho Climate Leadership U.S. ETFETHO20.82%
Global X Genomics & Biotechnology UCITS ETFGN0M.DE35.34%
Global X - Genomics & Biotechnology ETFGNOM35.40%
Ark Genomic Revolution Ucits ETF AccumUSDARKG.L36.38%

Funds with 10x Genomics among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price51.80 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

10x Genomics, Inc. (TXG)

TXG · NASDAQ · Healthcare
51.80 USD-9.72%
Sign up to track this stock
Benchmarks
KvantraRank78
Market cap6.29B
P/E NTMN/A
P/E TTMN/A
KvantraRank?78 / 100
Value
62
Quality
81
Momentum
99
Financialsin USD
20242025TTM2026E
ETFs that hold 10x Genomics
FundTickerPosition#Weight
Vanguard Russell 2000 ETFVTWO40.35%
Principal U.S. Small-Cap Multi-Factor ETFPSC40.84%
ARK Genomic Revolution ETFARKG27.87%
Vanguard Russell 2000 Growth ETFVTWG40.69%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC30.46%
Invesco Dorsey Wright Healthcare Momentum ETFPTH102.97%
Amplify Etho Climate Leadership U.S. ETFETHO20.82%
Global X Genomics & Biotechnology UCITS ETFGN0M.DE35.34%
Global X - Genomics & Biotechnology ETFGNOM35.40%
Ark Genomic Revolution Ucits ETF AccumUSDARKG.L36.38%

Funds with 10x Genomics among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current51.80 USD
Upside
Price consensus
Last year average price target
Current price51.80 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.

IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free